Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel weight loss regulators identified by Millennium scientists

July 28, 2004

Novel DPP-IV inhibitors in early development at Boehringer Ingelheim

July 28, 2004

Ezetimibe/simvastatin approved by FDA

July 27, 2004

New study evaluates effects of chromium picolinate in pre-diabetes patients

July 27, 2004

Fast track status for subcutaneous icatibant in HAE

July 27, 2004

Gene Logic acquires technology program from Millennium

July 27, 2004

Glucokinase activators described by Novartis

July 26, 2004

Farnesoid X receptor agonists

July 26, 2004

Phenylalanine derivatives for the treatment of diabetes claimed by Merck

July 23, 2004

Tentative approval for Cipher's CIP-Fenofibrate

July 23, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...